STOCK TITAN

Radiopharm Theranostics (RADX) director lists share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd director Paul Hopper has filed an initial Form 3 listing his ownership in Ordinary Shares and options. The filing shows direct ownership of 53,900,000 Ordinary Shares, plus additional indirect holdings through Kilinwata Investments Pty Ltd and his spouse. It also details multiple Option (right to buy) positions over Ordinary Shares with exercise prices between 0.0250 and 0.2000 and expirations ranging from 2026 to 2030, including grants that vest only if he remains a Director on specified future dates.

Positive

  • None.

Negative

  • None.
Insider HOPPER PAUL
Role null
Type Security Shares Price Value
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Option (right to buy) -- -- --
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Option (right to buy) — 2,666,667 shares (Direct, null); Option (right to buy) — 1,403,303 shares (Indirect, Held through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director); Ordinary Shares — 53,900,000 shares (Direct, null); Ordinary Shares — 250,000 shares (Indirect, Held by Deborah Coleman, who is Mr. Hopper's spouse.)
Footnotes (1)
  1. [object Object]
Direct Ordinary Shares 53,900,000 shares Total shares held directly by Paul Hopper following the reported holdings
Indirect shares via Kilinwata 93,571,428 shares Ordinary Shares held through Kilinwata Investments Pty Ltd as of the reported date
Indirect shares via spouse 250,000 shares Ordinary Shares held by Deborah Coleman, Mr. Hopper’s spouse
Option at 0.2000 exercise price 3,571,428 underlying shares Indirect Option (right to buy) over Ordinary Shares, expiring on 2026-11-30
Option at 0.0600 exercise price 27,500,000 underlying shares Direct Option (right to buy) over Ordinary Shares, expiring on 2026-08-24
Long-dated options at 0.0250 6,048,542 underlying shares Direct Option (right to buy) over Ordinary Shares, expiring on 2030-07-01
Option grant vesting 2026-09-30 2,666,667 options Options vest on 2026-09-30 if Mr. Hopper remains a Director
Option grant vesting 2027-09-30 2,666,666 options Options vest on 2027-09-30 subject to continued service as Director
Ordinary Shares financial
"security_title": "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Option (right to buy) financial
"security_title": "Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "0.0600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2030-07-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"options will vest on September 30, 2026 and 2,666,666 options will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
HOPPER PAUL

(Last)(First)(Middle)
SUITE 1 LEVEL 3, 62 LYGON STREET

(Street)
CARLTON SOUTH, VICTORIA3053

(City)(State)(Zip)

AUSTRALIA

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares53,900,000D
Ordinary Shares250,000IHeld by Deborah Coleman, who is Mr. Hopper's spouse.
Ordinary Shares93,571,428IHeld through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy)09/30/202509/30/2029Ordinary Shares2,666,667$0.06D
Option (right to buy) (1)09/30/2029Ordinary Shares5,333,333$0.06D
Option (right to buy)07/01/202306/30/2027Ordinary Shares1,403,303$0.17IHeld through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director
Option (right to buy)07/01/202406/30/2027Ordinary Shares1,403,303$0.17IHeld through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director
Option (right to buy)07/01/202506/30/2027Ordinary Shares1,403,723$0.17IHeld through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director
Option (right to buy)07/01/202607/01/2030Ordinary Shares6,046,729$0.025D
Option (right to buy)07/01/202707/01/2030Ordinary Shares6,046,729$0.025D
Option (right to buy)07/01/202807/01/2030Ordinary Shares6,048,542$0.025D
Option (right to buy)09/13/202408/24/2026Ordinary Shares27,500,000$0.06D
Option (right to buy)11/25/202211/30/2026Ordinary Shares3,571,428$0.2IHeld through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director
Explanation of Responses:
1. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided that Mr. Hopper is still a Director on such dates.
Remarks:
1. All exercise prices are in Australian dollars.
/s/ Paul Hopper05/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Paul Hopper’s Form 3 for Radiopharm Theranostics (RADX) disclose?

The Form 3 discloses Paul Hopper’s initial ownership in Ordinary Shares and stock options of Radiopharm Theranostics. It lists large direct and indirect share positions plus several option grants with specified exercise prices, vesting schedules, and expiration dates.

How many Radiopharm Theranostics (RADX) shares does Paul Hopper hold directly and indirectly?

The filing reports 53,900,000 Ordinary Shares held directly. It also shows indirect ownership of 93,571,428 Ordinary Shares through Kilinwata Investments Pty Ltd and 250,000 Ordinary Shares held by his spouse, Deborah Coleman.

What stock options over Radiopharm Theranostics (RADX) shares does Paul Hopper have?

Paul Hopper holds several Option (right to buy) positions over Ordinary Shares, with exercise prices of 0.0250, 0.0600, 0.1700, and 0.2000. These options cover millions of underlying shares and expire between 2026 and 2030.

How are Paul Hopper’s indirect Radiopharm Theranostics (RADX) holdings structured?

Indirect holdings are reported as Ordinary Shares and options held through Kilinwata Investments Pty Ltd, where he is sole shareholder and director, and shares held by his spouse. The filing attributes these positions as indirect beneficial ownership for disclosure purposes.

What does the footnote in Paul Hopper’s Radiopharm Theranostics (RADX) Form 3 explain?

The footnote explains an option grant on December 16, 2024. It states 2,666,667 options will vest on September 30, 2026 and 2,666,666 options on September 30, 2027, provided Mr. Hopper remains a Director on those dates.